Sugi Predict

Sugi Predict / Targets / DYRK2

DYRK2

Dual specificity tyrosine-phosphorylation-regulated kinase 2 · Q92630 · DYRK2 on Sugi Atlas →

47,536 patent compounds predicted against DYRK2, 30,040 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL513882 SCHEMBL513882 0.53 19/20
SCHEMBL102235 SCHEMBL102235 1.00 18/20
SCHEMBL102656 SCHEMBL102656 0.79 18/20
SCHEMBL102951 SCHEMBL102951 0.76 18/20
SCHEMBL102660 SCHEMBL102660 0.75 18/20
SCHEMBL102233 SCHEMBL102233 1.00 17/20
SCHEMBL102955 SCHEMBL102955 1.00 17/20
SCHEMBL103266 SCHEMBL103266 0.85 17/20
SCHEMBL102650 SCHEMBL102650 0.76 17/20
SCHEMBL102236 SCHEMBL102236 0.75 15/20
SCHEMBL102764 SCHEMBL102764 0.75 15/20
SCHEMBL102239 SCHEMBL102239 0.70 15/20
SCHEMBL102952 SCHEMBL102952 0.76 14/20
SCHEMBL102225 SCHEMBL102225 0.72 14/20
SCHEMBL102240 SCHEMBL102240 0.67 14/20
SCHEMBL103262 SCHEMBL103262 0.67 14/20
SCHEMBL513237 SCHEMBL513237 0.60 14/20
SCHEMBL102942 SCHEMBL102942 1.00 13/20
SCHEMBL103265 SCHEMBL103265 1.00 13/20
SCHEMBL102507 SCHEMBL102507 0.78 13/20

Clinical trials — most relevant to DYRK2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The Efficacy and Safety of Different Combination Regimens of Inetetamab in First-line Treatment of HER2 Positive Metastatic Breast Cancer PHASE4RECRUITING
The Efficacy and Safety of Deucravacitinib in Takayasu's Arteritis PHASE4NOT_YET_RECRUITING
Overcoming Endocrine Resistance in Metastatic Breast Cancer PHASE3UNKNOWN
Efficacy and Safety of 0.25% Timolol Gel in Healing Surgical Open Wounds PHASE2/PHASE3COMPLETED
A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer PHASE3UNKNOWN
Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer PHASE3COMPLETED
ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic Therapy PHASE2COMPLETED
Phase 2 Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatinib in Stage II/III Her2Neu+ Breast Cancer PHASE2COMPLETED
Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System PHASE2WITHDRAWN
Neoadjuvant GW572016 to Treat Breast Cancer PHASE2COMPLETED
Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast Cancer PHASE2RECRUITING
Study of AZD1775 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring TP53 Mutation as a Second-line Chemotherapy PHASE2COMPLETED
First-line Dasatinib Plus Conventional Chemotherapy in Adults With Newly Diagnosed Ph-Positive ALL PHASE2COMPLETED
Safety and Efficacy of the PAINLESS Nerve Growth Factor CHF6467 in Optic Pathway Glioma (OPG) PHASE2ACTIVE_NOT_RECRUITING
Deucravacitinib Rosacea PHASE2WITHDRAWN
Erlotinib Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia PHASE2COMPLETED
TSL2109 Capsules in Advanced Solid Tumor Patients: Safety, Tolerability, PK and Preliminary Efficacy PHASE1RECRUITING
Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2 PHASE1COMPLETED
Nilotinib in Huntington's Disease PHASE1UNKNOWN
Itacitinib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Identification of Treatment Concentrations of Defactinib or VS-6766 for the Treatment of Patients With Glioblastoma EARLY_PHASE1ACTIVE_NOT_RECRUITING
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma nanCOMPLETED
Myeloid Derived Suppressor Cells and Chronic Myeloid Leukemia nanUNKNOWN
Rostock International Parkinson's Disease Study (ROPAD) nanCOMPLETED
Pertuzumab in First Line Treatment of HER2-positive Metastatic Breast Cancer Patients nanUNKNOWN
Clinical Study on the Application of 18F-HER2 Affibody PET Imaging in HER2-Expressing Breast Cancer nanRECRUITING
Androgenetic Alopecia and the JAK-STAT Pathway nanCOMPLETED
PCM1-JAK2 in Therapy Related Neoplasms nanUNKNOWN
The Efficacy and Safety of Neoadjuvant Trastuzumab Plus Taxane With and Without Pertuzumab Therapy nanUNKNOWN
Effects of Growth Hormone and IGF-1 on Anabolic Signals and Stem Cell Recruitment in Human Skeletal Muscle nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a DYRK2 binder may also engage these)

ProteinNameSimilarity
Q5U4C9 — 1.000 Q5U4C9 →
Q5ZIU3 — 0.992 Q5ZIU3 →
Q5SN53 — 0.991 Q5SN53 →
DYRK3 Dual specificity tyrosine-phosphorylation-regulated kinase 3 0.991 landscape →
GSK3B Glycogen synthase kinase-3 beta 0.991 landscape →
Q5YJC2 — 0.990 Q5YJC2 →
P18266 — 0.990 P18266 →
Q9XTF3 — 0.990 Q9XTF3 →
Q501Q9 — 0.990 Q501Q9 →
Q9SJG9 — 0.990 Q9SJG9 →
Q6FKC6 — 0.989 Q6FKC6 →
Q4V8A3 — 0.989 Q4V8A3 →
Q63470 — 0.989 Q63470 →
Q9WV60 — 0.989 Q9WV60 →
P51138 — 0.989 P51138 →
Q4R6S5 — 0.989 Q4R6S5 →
Q2NL51 — 0.988 Q2NL51 →
Q922Y0 — 0.988 Q922Y0 →
Q9LV37 — 0.988 Q9LV37 →
Q9NAH6 — 0.988 Q9NAH6 →
Q8W4J2 — 0.988 Q8W4J2 →
Q05512 — 0.988 Q05512 →
A0A1D9QMS2 — 0.988 A0A1D9QMS2 →
Q19469 — 0.987 Q19469 →
Q8VZD5 — 0.987 Q8VZD5 →
Q96287 — 0.987 Q96287 →
B3M301 — 0.987 B3M301 →
A8WJR8 — 0.987 A8WJR8 →
Q0IJ08 — 0.987 Q0IJ08 →
B4NBP4 — 0.987 B4NBP4 →